Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Income from Continuing Operations (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Income from Continuing Operations for 4 consecutive years, with 2316786.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 7.23% to 2316786.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 605630.0, a 87.76% increase, with the full-year FY2024 number at 583631.0, up 27.67% from a year prior.
  • Income from Continuing Operations was 2316786.0 for Q3 2025 at 60 Degrees Pharmaceuticals, down from 1734651.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5323108.0 in Q4 2024 to a low of 4174226.0 in Q2 2024.
  • A 4-year average of 813108.79 and a median of 1805976.0 in 2025 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: surged 1804.91% in 2023, then tumbled 538.64% in 2025.
  • 60 Degrees Pharmaceuticals' Income from Continuing Operations stood at 1669654.0 in 2022, then soared by 157.54% to 960644.0 in 2023, then soared by 454.12% to 5323108.0 in 2024, then tumbled by 143.52% to 2316786.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Income from Continuing Operations are 2316786.0 (Q3 2025), 1734651.0 (Q2 2025), and 1877301.0 (Q1 2025).